---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-040641"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:58:21.098925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M

## Summary
- ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.
- Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.
- KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.
- Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.
- Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing.

## SEC filing metadata
- accession: 0001104659-25-040641
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/0001104659-25-040641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-040641
- JSON: https://secwatch.observer/filing/0001104659-25-040641.json
- Plain text: https://secwatch.observer/filing/0001104659-25-040641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.